Hb Bart's hydrops fetalis (alpha-thalassemia major)

For the HBA1 c.96-1G>A splice acceptor variant, which disrupts normal splicing of exon 2 and causes loss of functional alpha-globin, precision gene editing (adenine base editing or prime editing) in autologous hematopoietic stem cells offers a theoretically curative approach. Adenine base editing (ABE) could directly revert the A-to-G change at the canonical splice acceptor site, restoring normal splicing without double-strand breaks. This is particularly relevant because Hb Bart's hydrops fetalis requires loss of all four alpha-globin gene copies — correcting even one or two copies in sufficient HSCs could convert a lethal phenotype to a manageable carrier or trait state.

Alpha-thalassemia major (Hb Bart's hydrops fetalis) results from deletion or inactivation of all four alpha-globin genes (two HBA1 + two HBA2 copies). It is typically caused by homozygous --SEA or other large deletions, but point mutations like c.96-1G>A at splice acceptor sites can functionally inactivate individual alpha-globin genes. The c.96-1G>A variant disrupts the invariant AG dinucleotide at the intron 1/exon 2 boundary, causing exon skipping or cryptic splice site activation, producing no functional alpha-globin from this allele. Adenine base editors (ABE8e and variants) have demonstrated high-efficiency A-to-G editing at splice sites in HSCs in preclinical models for other hemoglobinopathies. The success of exa-cel (exagamglogene autotemcel, approved for SCD and beta-thalassemia) validates the ex vivo HSC gene editing paradigm: HSCs are harvested, edited, and reinfused after myeloablative conditioning. For alpha-thalassemia, the same platform could be adapted with a guide RNA targeting the c.96-1 position.

Hb Bart's hydrops fetalis is typically diagnosed prenatally and is usually lethal in utero or perinatally, creating an extremely narrow treatment window. Ex vivo HSC editing would require postnatal survival (via intrauterine transfusion) and neonatal stem cell collection, which is technically challenging. The c.96-1G>A variant is a point mutation causing alpha-thal, but most Hb Bart's cases involve large deletions (--SEA/--SEA) where base editing is not applicable — this limits the patient population for this specific approach. No clinical trial for gene editing in alpha-thalassemia major has been registered. Myeloablative conditioning in a severely hydrops neonate carries extreme risk. The approach assumes compound heterozygosity where at least some alleles carry correctable point mutations rather than deletions.

Base Editing (ABE8e) via RNP electroporation (ex vivo) delivery is a rationale-driven therapeutic strategy for Hb Bart's hydrops fetalis (alpha-thalassemia major) targeting the HBA1/HBA2 c.358C>T (p.Pro120Ser) variant (Pathogenic, missense variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: Blood/HSC. Therapeutic goal: Restore sufficient alpha-globin expression in fetal/newborn erythroid cells to convert lethal Hb Bart's hydrops fetalis into survivable phenotype or cure transfusion dependence. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity Low.

1. Molecular basis: HBA1/HBA2 NM_000558.5(HBA1):c.358C>T (p.Pro120Ser) is classified as Pathogenic (ClinVar variation ID 811900). Molecular consequence: missense variant. Protein change: P120S. 2. Epidemiology: Executed all paper-assigned subtasks from plan.jsonl for Hb Bart's hydrops fetalis / alpha-thalassemia major. For severity/urgency (S1-S3, U1-U2), collected cohort and registry data on survival, neurodevelopment, organ damage, healthcare utilization, and chronic transfusion/chelation burden, plus re 3. Standard of care: Executed all web-assigned subtasks from plan.jsonl: (1) disease definition/natural history and patient journey; (2) urgency U1–U3 including current standard of care, access, and epidemiology; (3) therapeutic landscape across modalities and clinical development status; (4) regulatory and safety persp 4. Pipeline: Orphanet and linked rare disease resources classify hemoglobin Bart’s hydrops fetalis (alpha-thalassemia major) as a severe, typically lethal perinatal disorder caused by deletion or inactivation of all four alpha-globin genes. Clinical course is marked by fetal hydrops, severe anemia, cardiomegaly, 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting HBA1/HBA2 c.358C>T (p.Pro120Ser) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.